FGFR Inhibitors for Treatment of Primary CNS Tumors

Author(s)Sydney E. Schultz, PharmD, Jason N. Barreto, PharmD, Carolyn Mead-Harvey, MS

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

Dysregulation of fibroblast growth factor receptor (FGFR) signaling has been observed in central nervous system (CNS) tumors, with FGFR inhibitors associated with objective response rates between 10% and 29%.